Lessons from the withdrawal of rofecoxib: France has policy for overall assessment of public health impact of new drugs

類似資料

• Lessons from the withdrawal of rofecoxib: Observational studies should not be forgotten
  著者:: Oakley, Godfrey
  出版事項: (2004)
• Lessons from the withdrawal of rofecoxib: Patients would be safer if drug companies disclosed adverse events before licensing
  著者:: Dieppe, Paul A, 等
  出版事項: (2004)
• Lawsuits mount in wake of rofecoxib (Vioxx) withdrawal
  著者:: Kondro, Wayne
  出版事項: (2004)
• Health Impact Assessment: Necessary but Not Sufficient for Healthy Public Policy
  著者:: Gottlieb, Laura M., 等
  出版事項: (2012)
• The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies
  著者:: Paget, John, 等
  出版事項: (2020)